Treatment of acute myelogenous leukemia in patients over 50 years of age with V‐TAD: A southwest oncology group study

American Journal of Hematology

Volumn 48, Issue 4, 1995, Pages 228-232

  Bigelow, Carolyn L ^a   Kopecky, Kenneth ^b   Files, Joe C ^a   Head, David ^c   Lipschitz, David A ^d   Grever, Michael ^e   Appelbaum, Frederick R ^f  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

Author keywords

Acute myelogenous leukemia (AML); chemotherapy; elderly

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FEMALE; HUMAN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; THIOGUANINE; UNITED STATES;

EID: 0028942918     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.2830480404     Document Type: Article

References (21)

1. Acute myeloid leukaemia: Recent advances in therapy
2. Factors related to length of complete remission of acute leukemia
3. Results of aggressive chemotherapy for acute nonlymphoblastic leukemia in adults
4. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age‐specific rate of incidence and of complete remission
5. Relationship between patient's age, bone marrow karyotype, and outcome of induction therapy in acute myelogenous leukemia
6. Age and treatment of nonlymphoblastic leukemia
7. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia
8. Principal results of the medical resesrch council's 8th annual myeloid leukaemia trial
9. Causes of initial remission induction failure in acute myelogenous leukemia
10. Acute myeloblastic leukemia in elderly patients
11. Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside
12. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia
13. Etoposide in combination with cytarabine, Doxorubicin, and 6‐thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age
14. Review of etoposide single agent activity
15. Etopside in the treatment of acute leukemia in adults
16. A phase II trial of VP‐16‐213 in adults with refractory acute myeloid leukemia: An eastern cooperative oncology group study
17. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6‐thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly
18. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study
19. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP)
20. Treatment of acute myeloid leukemia in elderly patients
21. Comparison of three remission induction regimens and two postinduction strategies for the treatment of nonlymphocytic leukemia: A cancer and leukemia group B study